Isolated ACTH deficiency probably induced by autoimmune-related mechanism evoked with nivolumab

Keiko Kitajima, Kenji Ashida, Naoko Wada, Ryoko Suetsugu, Yukina Takeichi, Shohei Sakamoto, Hiroshi Uchi, Takamitsu Matsushima, Motoaki Shiratsuchi, Keizo Ohnaka, Masutaka Furue, Masatoshi Nomura

研究成果: ジャーナルへの寄稿記事

20 引用 (Scopus)

抄録

Nivolumab, an anti-programmed death-1 antibody, is a breakthrough treatment for several malignancies. Its specific adverse effects caused by autoimmunity are termed immune-related adverse events, which involve several endocrine dysfunctions. Herein, we report two cases of isolated adrenocorticotropic hormone (ACTH) deficiency induced by nivolumab for the treatment of metastatic malignant melanoma. Case 1 was a 39-year-old man and Case 2 was a 50-year-old woman, both of whom presented with progressive melanoma. After 13 courses of nivolumab administration, both cases were diagnosed with adrenal insufficiency. Despite their basal serum ACTH and cortisol levels being low with little response to corticotropin-releasing hormone loading, other anterior pituitary hormone levels were preserved. Based on these endocrinological data, isolated ACTH deficiency was diagnosed. Magnetic resonance imaging showed normal pituitary glands, excluding hypophysitis. Finally, hydrocortisone replacement enabled the patients to continue nivolumab treatment. Therefore, it is important to consider isolated ACTH syndrome as a possible and potentially severe immune-related adverse event of nivolumab, even when head magnetic resonance imaging of affected cases does not show enlargement. We should not misdiagnose hidden immune-related adverse events behind general complaints of malignancies such as general malaise and appetite loss, to allow successful treatment using this beneficial immune checkpoint inhibitor.

元の言語英語
記事番号hyx018
ページ(範囲)463-466
ページ数4
ジャーナルJapanese journal of clinical oncology
47
発行部数5
DOI
出版物ステータス出版済み - 5 1 2017

Fingerprint

Adrenocorticotropic Hormone
Hydrocortisone
Melanoma
Magnetic Resonance Imaging
Anterior Pituitary Hormones
Adrenal Insufficiency
Corticotropin-Releasing Hormone
Appetite
Pituitary Gland
Therapeutics
Diagnostic Errors
Autoimmunity
Neoplasms
Head
nivolumab
Adrenocorticotropic hormone deficiency
Antibodies
Serum
Hypophysitis

All Science Journal Classification (ASJC) codes

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

これを引用

Isolated ACTH deficiency probably induced by autoimmune-related mechanism evoked with nivolumab. / Kitajima, Keiko; Ashida, Kenji; Wada, Naoko; Suetsugu, Ryoko; Takeichi, Yukina; Sakamoto, Shohei; Uchi, Hiroshi; Matsushima, Takamitsu; Shiratsuchi, Motoaki; Ohnaka, Keizo; Furue, Masutaka; Nomura, Masatoshi.

:: Japanese journal of clinical oncology, 巻 47, 番号 5, hyx018, 01.05.2017, p. 463-466.

研究成果: ジャーナルへの寄稿記事

Kitajima, K, Ashida, K, Wada, N, Suetsugu, R, Takeichi, Y, Sakamoto, S, Uchi, H, Matsushima, T, Shiratsuchi, M, Ohnaka, K, Furue, M & Nomura, M 2017, 'Isolated ACTH deficiency probably induced by autoimmune-related mechanism evoked with nivolumab', Japanese journal of clinical oncology, 巻. 47, 番号 5, hyx018, pp. 463-466. https://doi.org/10.1093/jjco/hyx018
Kitajima, Keiko ; Ashida, Kenji ; Wada, Naoko ; Suetsugu, Ryoko ; Takeichi, Yukina ; Sakamoto, Shohei ; Uchi, Hiroshi ; Matsushima, Takamitsu ; Shiratsuchi, Motoaki ; Ohnaka, Keizo ; Furue, Masutaka ; Nomura, Masatoshi. / Isolated ACTH deficiency probably induced by autoimmune-related mechanism evoked with nivolumab. :: Japanese journal of clinical oncology. 2017 ; 巻 47, 番号 5. pp. 463-466.
@article{67852d0685e748c0a8629bedfcbc7aef,
title = "Isolated ACTH deficiency probably induced by autoimmune-related mechanism evoked with nivolumab",
abstract = "Nivolumab, an anti-programmed death-1 antibody, is a breakthrough treatment for several malignancies. Its specific adverse effects caused by autoimmunity are termed immune-related adverse events, which involve several endocrine dysfunctions. Herein, we report two cases of isolated adrenocorticotropic hormone (ACTH) deficiency induced by nivolumab for the treatment of metastatic malignant melanoma. Case 1 was a 39-year-old man and Case 2 was a 50-year-old woman, both of whom presented with progressive melanoma. After 13 courses of nivolumab administration, both cases were diagnosed with adrenal insufficiency. Despite their basal serum ACTH and cortisol levels being low with little response to corticotropin-releasing hormone loading, other anterior pituitary hormone levels were preserved. Based on these endocrinological data, isolated ACTH deficiency was diagnosed. Magnetic resonance imaging showed normal pituitary glands, excluding hypophysitis. Finally, hydrocortisone replacement enabled the patients to continue nivolumab treatment. Therefore, it is important to consider isolated ACTH syndrome as a possible and potentially severe immune-related adverse event of nivolumab, even when head magnetic resonance imaging of affected cases does not show enlargement. We should not misdiagnose hidden immune-related adverse events behind general complaints of malignancies such as general malaise and appetite loss, to allow successful treatment using this beneficial immune checkpoint inhibitor.",
author = "Keiko Kitajima and Kenji Ashida and Naoko Wada and Ryoko Suetsugu and Yukina Takeichi and Shohei Sakamoto and Hiroshi Uchi and Takamitsu Matsushima and Motoaki Shiratsuchi and Keizo Ohnaka and Masutaka Furue and Masatoshi Nomura",
year = "2017",
month = "5",
day = "1",
doi = "10.1093/jjco/hyx018",
language = "English",
volume = "47",
pages = "463--466",
journal = "Japanese Journal of Clinical Oncology",
issn = "0368-2811",
publisher = "Oxford University Press",
number = "5",

}

TY - JOUR

T1 - Isolated ACTH deficiency probably induced by autoimmune-related mechanism evoked with nivolumab

AU - Kitajima, Keiko

AU - Ashida, Kenji

AU - Wada, Naoko

AU - Suetsugu, Ryoko

AU - Takeichi, Yukina

AU - Sakamoto, Shohei

AU - Uchi, Hiroshi

AU - Matsushima, Takamitsu

AU - Shiratsuchi, Motoaki

AU - Ohnaka, Keizo

AU - Furue, Masutaka

AU - Nomura, Masatoshi

PY - 2017/5/1

Y1 - 2017/5/1

N2 - Nivolumab, an anti-programmed death-1 antibody, is a breakthrough treatment for several malignancies. Its specific adverse effects caused by autoimmunity are termed immune-related adverse events, which involve several endocrine dysfunctions. Herein, we report two cases of isolated adrenocorticotropic hormone (ACTH) deficiency induced by nivolumab for the treatment of metastatic malignant melanoma. Case 1 was a 39-year-old man and Case 2 was a 50-year-old woman, both of whom presented with progressive melanoma. After 13 courses of nivolumab administration, both cases were diagnosed with adrenal insufficiency. Despite their basal serum ACTH and cortisol levels being low with little response to corticotropin-releasing hormone loading, other anterior pituitary hormone levels were preserved. Based on these endocrinological data, isolated ACTH deficiency was diagnosed. Magnetic resonance imaging showed normal pituitary glands, excluding hypophysitis. Finally, hydrocortisone replacement enabled the patients to continue nivolumab treatment. Therefore, it is important to consider isolated ACTH syndrome as a possible and potentially severe immune-related adverse event of nivolumab, even when head magnetic resonance imaging of affected cases does not show enlargement. We should not misdiagnose hidden immune-related adverse events behind general complaints of malignancies such as general malaise and appetite loss, to allow successful treatment using this beneficial immune checkpoint inhibitor.

AB - Nivolumab, an anti-programmed death-1 antibody, is a breakthrough treatment for several malignancies. Its specific adverse effects caused by autoimmunity are termed immune-related adverse events, which involve several endocrine dysfunctions. Herein, we report two cases of isolated adrenocorticotropic hormone (ACTH) deficiency induced by nivolumab for the treatment of metastatic malignant melanoma. Case 1 was a 39-year-old man and Case 2 was a 50-year-old woman, both of whom presented with progressive melanoma. After 13 courses of nivolumab administration, both cases were diagnosed with adrenal insufficiency. Despite their basal serum ACTH and cortisol levels being low with little response to corticotropin-releasing hormone loading, other anterior pituitary hormone levels were preserved. Based on these endocrinological data, isolated ACTH deficiency was diagnosed. Magnetic resonance imaging showed normal pituitary glands, excluding hypophysitis. Finally, hydrocortisone replacement enabled the patients to continue nivolumab treatment. Therefore, it is important to consider isolated ACTH syndrome as a possible and potentially severe immune-related adverse event of nivolumab, even when head magnetic resonance imaging of affected cases does not show enlargement. We should not misdiagnose hidden immune-related adverse events behind general complaints of malignancies such as general malaise and appetite loss, to allow successful treatment using this beneficial immune checkpoint inhibitor.

UR - http://www.scopus.com/inward/record.url?scp=85026218407&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85026218407&partnerID=8YFLogxK

U2 - 10.1093/jjco/hyx018

DO - 10.1093/jjco/hyx018

M3 - Article

C2 - 28334791

AN - SCOPUS:85026218407

VL - 47

SP - 463

EP - 466

JO - Japanese Journal of Clinical Oncology

JF - Japanese Journal of Clinical Oncology

SN - 0368-2811

IS - 5

M1 - hyx018

ER -